November 16, 2021 10:21 AM ESTUpdated 11:14 AM

Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA

Zachary Brennan

Senior Editor

Paul Schloesser

Associate Editor

Following a similar deal forged by Merck for its Covid-19 drug molnupiravir, Pfizer on Tuesday agreed to allow the UN-backed Medicines Patent Pool to license …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA

Zachary Brennan

Senior Editor

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Covid-19 roundup: Pfiz­er li­cens­es its pill to the Med­i­cines Patent Pool; NYC joins states in au­tho­riz­ing boost­ers for all adults ahead of FDA

Senior Editor

Associate Editor

Sign up to read this article for free.

Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA